This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geerdes-Fenge, H. F.
Right arrow Articles by Lode, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geerdes-Fenge, H. F.
Right arrow Articles by Lode, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2000, p. 3478-3480, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Levofloxacin Pharmacokinetics and Serum Bactericidal Activities against Five Enterobacterial Species

Hilte F. Geerdes-Fenge,1,* Axel Wiedersich,1 S. Wagner,2 Karl-Heinz Lehr,3 Peter Koeppe,4 and Hartmut Lode1

Department of Pulmonary and Infectious Diseases1 and Department of Clinical Microbiology,2 City Hospital Zehlendorf/Heckeshorn, Freie Universität Berlin, 14109 Berlin, Department of Drug Metabolism & Pharmacokinetics, Hoechst-Marion-Roussel, 65926 Frankfurt am Main,3 and Department of Medical Physics and Laser Medicine, Klinikum Benjamin Franklin, Freie Universität Berlin, 12200 Berlin,4 Germany

Received 21 June 1999/Returned for modification 12 September 1999/Accepted 11 September 2000

After oral administration of 500 mg of levofloxacin to 12 volunteers, we investigated the pharmacokinetics and serum bactericidal activities (SBAs) against five strains of members of the family Enterobacteriaceae. Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 ± 0.57 mg/liter; area under the concentration-time curve, 43.6 ± 6.23 mg · h/liter; elimination half-life 4.23 ± 0.87 h. SBAs were present for 24 h against Escherichia coli and Citrobacter freundii. The SBAs at 1, 12, and 24 h after administration against E. coli were 1:108, 1:29, and 1:7, respectively, and those against Citrobacter freundii were 1:74, 1:25, and 1:7, respectively. The SBAs were present for 12 h against the other three organisms tested. The SBAs against Serratia marcescens were 1:28 and 1:9 at 1 and 12 h, respectively; the SBAs against Klebsiella pneumoniae were 1:25 and 1:7 at 1 and 12 h, respectively; and the SBAs against Enterobacter cloacae were 1:24 and 1:10 at 1 and 12 h, respectively.

* Corresponding author. Mailing address: Department of Pulmonary and Infectious Diseases, City Hospital Zehlendorf/Heckeshorn, affil. Freie Universität Berlin, Zum Heckeshorn 33, D-14109 Berlin, Germany. Phone: 49-30-8002-2222. Fax: 49-30-8002-2623. E-mail: haloheck{at}zedat.fu-berlin.de.

Antimicrobial Agents and Chemotherapy, December 2000, p. 3478-3480, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Dupont, P., Hocquet, D., Jeannot, K., Chavanet, P., Plesiat, P. (2005). Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa. J Antimicrob Chemother 55: 518-522 [Abstract] [Full Text]  
  • Maurin, M., Bakken, J. S., Dumler, J. S. (2003). Antibiotic Susceptibilities of Anaplasma (Ehrlichia) phagocytophilum Strains from Various Geographic Areas in the United States. Antimicrob. Agents Chemother. 47: 413-415 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»